PMID- 22653439
OWN - NLM
STAT- MEDLINE
DCOM- 20130607
LR  - 20220311
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 251
IP  - 2
DP  - 2013 Feb
TI  - Spectral-domain optical coherence tomography (SD-OCT) patterns and response to 
      intravitreal bevacizumab therapy in macular edema associated with branch retinal 
      vein occlusion.
PG  - 501-8
LID - 10.1007/s00417-012-2067-8 [doi]
AB  - BACKGROUND: To evaluate the baseline spectral-domain optical coherence tomography 
      (SD-OCT) characteristics of macular edema (ME) due to branch retinal vein 
      occlusion (BRVO) for visual outcome after intravitreal bevacizumab injection. 
      METHODS: Fifty-nine patients treated in one eye with intravitreal bevacizumab for 
      ME due to BRVO were retrospectively reviewed. Stepwise multiple regression 
      analysis was used to evaluate the relative contribution of several variables, 
      including SD-OCT characteristics such as photoreceptor inner segment/outer 
      segment (IS/OS) integrity and external limiting membrane (ELM status), baseline 
      best-corrected visual acuity (BCVA), and baseline central retinal thickness (CRT) 
      with final visual outcome. RESULTS: Thirty-one patients (52.5 %) had disrupted 
      photoreceptor IS/OS integrity. The mean BCVA improved significantly from 0.50 
      logMAR (20/63 Snellen equivalent) to 0.10 logMAR (20/25 Snellen equivalent) in 
      the intact photoreceptor group (p = 0.000, paired t-test). However, the mean BCVA 
      was improved in the disrupted photoreceptor group, from 1.10 logMAR (20/252 
      Snellen equivalent) to 0.94 logMAR (20/174 Snellen equivalent), which was not 
      statistically significant (p = 0.177, paired t-test). ELM was disrupted in 23 
      patients (39.0 %). The mean BCVA improved significantly from 0.63 logMAR (20/85 
      Snellen equivalent) to 0.26 logMAR (20/36 Snellen equivalent) in the intact ELM 
      group (p = 0.000, paired t-test), however, not significantly improved in the 
      disrupted ELM group, from 1.09 logMAR (20/246 Snellen equivalent) to 1.01 logMAR 
      (20/205 Snellen equivalent) (p = 0.563, paired t-test). The strongest individual 
      predictor of final BCVA among patients with ME due to BRVO was the integrity of 
      photoreceptor IS/OS layer on SD OCT (r (2) = 0.514, p = 0.000, stepwise multiple 
      regression), but the most efficient model was the combination of the 
      photoreceptor IS/OS integrity, ELM status, and baseline BCVA (r(2) = 0.671, p = 
      0.000, stepwise multiple regression). The strongest predictor of final BCVA was 
      the status of photoreceptor IS/OS integrity (beta = 0.532, p = 0.000, stepwise 
      multiple regression), followed by ELM status (beta = 0.325, p = 0.006, stepwise 
      multiple regression), and the baseline BCVA (beta = 0.238, p = 0.013, stepwise 
      multiple regression). CONCLUSION: Our results suggest that baseline SD-OCT 
      characteristics, the status of photoreceptor IS/OS and ELM can be helpful in 
      predicting the final visual outcome after intravitreal bevacizumab injection in 
      these patients.
FAU - Kang, Hae Min
AU  - Kang HM
AD  - Institute of Vision Research, Department of Ophthalmology, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Chung, Eun Jee
AU  - Chung EJ
FAU - Kim, Yong Min
AU  - Kim YM
FAU - Koh, Hyoung Jun
AU  - Koh HJ
LA  - eng
PT  - Journal Article
DEP - 20120601
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use
MH  - Bevacizumab
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/diagnosis/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Retinal Photoreceptor Cell Inner Segment/pathology
MH  - Retinal Photoreceptor Cell Outer Segment/pathology
MH  - Retinal Vein Occlusion/*complications/diagnosis
MH  - Retrospective Studies
MH  - *Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/physiology
EDAT- 2012/06/02 06:00
MHDA- 2013/06/08 06:00
CRDT- 2012/06/02 06:00
PHST- 2012/02/09 00:00 [received]
PHST- 2012/05/14 00:00 [accepted]
PHST- 2012/04/17 00:00 [revised]
PHST- 2012/06/02 06:00 [entrez]
PHST- 2012/06/02 06:00 [pubmed]
PHST- 2013/06/08 06:00 [medline]
AID - 10.1007/s00417-012-2067-8 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):501-8. doi: 
      10.1007/s00417-012-2067-8. Epub 2012 Jun 1.